Bifidobacterium infantis is a dominant early commensal beneficial bacterium in the infant gut, classified as the infant subspecies of Bifidobacterium longum. Capable of efficiently utilizing human milk oligosaccharides (HMOs), it acts as a "pioneer bacterium" in the infant intestine and plays a central role in infant gut health, immune development and nutrient absorption.

1. HMO specific metabolic capacity: Bifidobacterium infantis is a preferred probiotic strain for HMO fortified formulations. It utilizes HMOs as a carbon source, adapts to the infant gut environment, and helps establish early intestinal microecology.

2. Complete compliance qualifications: Food grade strain with GRAS and QPS eligibility. It is suitable for a wide range of finished products including infant formula powder, drops and solid beverages.

3. Production and formulation benefits: Manufactured via submerged liquid fermentation and freeze drying to produce free flowing powder. Micro encapsulation is available to enhance processing stability. Multiple CFU specifications can be custom made, and test samples are offered for evaluation.

Infant formula foods: Bifidobacterium infantis can be incorporated into infant targeted products, such as probiotic drops and infant foods.

Dietary supplements: It can be formulated into synbiotic blends together with prebiotics including HMO and FOS. Suitable for solid beverages, capsules and tablets.

Animal nutrition: Used as a feed additive for young animals to improve the survival rate of juvenile livestock.